Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248

Journal of Medicinal Chemistry

Volumn 56, Issue 4, 2013, Pages 1670-1676

  Regueiro Ren, Alicia ^a   Simmermacher Mayer, Jean ^a   Sinz, Michael ^a   Johnson, Kim A ^a   Huang, Xiaohua Stella ^a   Jenkins, Susan ^a   Parker, Dawn ^a   Rahematpura, Sandhya ^a   Zheng, Ming ^a   Meanwell, Nicholas A ^a   Kadow, John F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINIUM; AMMONIUM DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 585248; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS ATTACHMENT; VIRUS INHIBITION;

EID: 84874619804     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301638a     Document Type: Article

References (16)

1. Regueiro-Ren, A.; Xue, Q. M.; Swidorski, J. J.; Gong, Y.-F.; Mathew, M.; Parker, D. D.; Yang, Z.; Eggers, B.; D'Arienzo, C.; Sun, Y.; Malinowski, J.; Gao, Q.; Wu, D.; Langley, D. R.; Colonno, R. J.; Chien, C.; Grasela, D. M.; Zheng, M.; Lin, P.-F.; Meanwell, N. A.; Kadow, J. F. Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 12. Structure-Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoyl-piperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1- yl-1 H -pyrrolo[2,3- c ]pyridin-3-yl)-ethane-1,2-dione (BMS-585248). J. Med. Chem. 2013, DOI: 10.1021/jm3016377.
2. Kadow, J. F.; Ueda, Y.; Meanwell, N. A.; Connolly, T. P.; Wang, T.; Chen, C.-P.; Yeung, K.-S.; Zhu, J.; Bender, J. A.; Yang, Z.; Parker, D.; Lin, P.-F.; Colonno, R. J.; Mathew, M.; Morgan, D.; Zheng, M.; Chien, C.; Grasela, D. Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1 H -pyrrolo[2,3- c ]pyridin-3-yl)-2-oxoethanone (BMS-488043) J. Med. Chem. 2012, 55, 2048-2056
3. Regueiro-Ren, A.; Jenkins, S. M.; Kim, S.; Mosure, K.; Rahematpura, S.; Simmermacher, J.; Sinz, M.; Zheng, M.; Johnson, K.; Meanwell, N. A.; Kadow, J. F. Novel ammonium prodrug: synthesis, pharmacokinetics, mechanism of release and scope. Abstracts of Papers, 240th ACS National Meeting and Exposition, Boston, MA, August 22-26, 2010, MEDI-421.
4. Kadow, J. F.; Regueiro-Ren, A. Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents. U.S. Patent US 20060142298, 2006.
5. Patterson, L H; McKeown, S R; Robson, T.; Gallagher, R.; Raleigh, S M; Orr, S. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation Anti-Cancer Drug Des. 1999, 14, 473-486 (Pubitemid 30258967)
6. Patterson, L. H. Rationale for the use of aliphatic N -oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent Cancer Metastasis Rev. 1993, 12, 119-134 (Pubitemid 23220676)
7. Bottaro, J. C. Stereospecific conversion of olefins into aziridines by p -tolylsulfonylhydroxylamine J. Chem. Soc., Chem. Commun. 1980, 560-561
8. Raap, R. Amination of tetrazoles with hydroxylamine- O -sulfonic acid: 1-and 2-aminotetrazoles Can. J. Chem. 1969, 47, 3677-3681
9. Bellettini, J. R.; Olson, E. R.; Teng, M.; Miller, M. J. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; Wiley: New York, 1995; Vol 3, pp 2189-2190.
10. Goeptar, A.; Scheerens, H.; Vermeulen, N. Oxygen and Xenobiotic Reductase Activities of Cytochromoe P450 Crit. Rev. Toxicol. 1995, 25 (1) 25-65
11. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11, 740-746
12. Broccatelli, F.; Cruciani, G.; Benet, L. Z.; Oprea, T. I. BDDCS Class Prediction for New Molecular Entities Mol. Pharmaceutics 2012, 9, 570-580
13. Sousa, T.; Paterson, R.; Moore, V.; Carlsson, A.; Abrahamsson, B.; Basit, A. The gastrointestinal microbiota as a site for the biotransformation of drugs Int. J. Pharm. 2008, 363, 1-25
14. Bonjouklian, R.; Dally, R. D.; De Dios, A.; Del Prado, C.; Miriam, F.; Dominguez-Fernandez, C.; Jaramillo Aguado, C.; Lopez de Uralde-Garmendia, B.; Montero Salgado, C.; Shepherd, T. A. Kinase inhibitors. PCT WO 2005080380, 2005.
15. Berry, M. N.; Edwards, A. M.; Barritt, G. J. Laboratory Techniques in Biochemistry and Molecular Biology: Isolated Hepatocytes Preparation, Properties and Applications; Elsevier: Amsterdam, 1991.
16. Watanabe, K.; Yamashita, S.; Furuno, K.; Kawasaki, H.; Gomita, Y. Metabolism of omeprazole by gut flora in rats J. Pharm. Sci. 1995, 84, 516-517